Official AMFI data
Arthkar — Understand Money, Invest Smartly
Tata

Tata India Pharma & Healthcare Fund

Sectoral / ThematicEquityVery High risk Rank 42 of 157

NAV · Direct-Growth

₹39.77+0.15+0.39%

As of 18 Aug 2026 · AMFI

NAV growth+9.6%
Aug ’25Aug ’26
Arthkar verdictA balanced read

Returns

Beats category

1Y, 3Y, 5Y all ahead

Cost

Average

0.67% vs NaN% peers

Volatility

Above average

16.4% vs 16.3% cat (3Y)

Consistency

Steady

positive in 7 of 11 years

Beats its Sectoral / Thematic category on 1Y, 3Y & 5Y — but has run more volatile than peers.

1Y return

+9.6%

+0.1 vs cat

3Y CAGR

+20.5%

+3.3 vs cat

5Y CAGR

+15.2%

+0.4 vs cat

AUM

₹1.4K Cr

fund size

Expense

0.67%

direct plan

Volatility 3Y

16.4%

▲ vs 16.3%

Go deeper on Tata India Pharma & Healthcare Fund

Two data-only views, computed from this fund's real NAV history — no projections.

In plain English

Tata India Pharma & Healthcare Fund is a Sectoral / Thematic scheme from Tata. The portfolio is ~99% in equities. Long-run track record: about 15.2% CAGR over 5 years. Volatility is typical for equity — 20–30 % drawdowns happen during market stress. Worst historical drawdown: -20% in Aug 2017, recovered in 13 months. Wrong fit if you need this money in less than 7 years.

Auto-generated from holdings, returns and risk data. No paid placement, no copy-pasted boilerplate.

NAV history

Showing Direct · Growth · INF277K019A3

NAV (Direct-Growth)

₹39.7747

Last 1Y

+9.62%

Aug 25Min ₹32.80 · Max ₹40.16 · 247 ptsAug 26

Drawdown stories

The crashes you should know about — and how long the fund took to recover.

Aug 2017

-19.8%

Peak ₹10.13 on 1 Feb 2016 → trough ₹8.12 on 21 Aug 2017 (19 months down).

Recovered in 13 months· 31 Aug 2018

Mar 2020

-18.5%

Peak ₹10.90 on 19 Feb 2020 → trough ₹8.88 on 23 Mar 2020 (1 months down).

Recovered in 1 months· 8 Apr 2020

Jun 2022

-17.3%

Peak ₹20.14 on 15 Sept 2021 → trough ₹16.67 on 17 Jun 2022 (9 months down).

Recovered in 12 months· 26 Jun 2023

Feb 2025

-16.8%

Peak ₹36.92 on 2 Jan 2025 → trough ₹30.72 on 28 Feb 2025 (2 months down).

Recovered in 15 months· 11 May 2026

Computed from the full NAV history. We show drawdowns deeper than 10%, sorted by depth.

Honesty score

A 1–5 grade on the dimensions other sites won't surface — expense bloat, AUM bloat, concentration, mandate compliance.

4

Honesty score

4 / 5

Solid scheme on the dimensions we check. No red flags.

  • Expense ratio

    0.67% — typical for category.

  • AUM size

    ₹1.4K Cr.

  • Sector concentration

    Top 3 sectors = 99.6% — heavy concentration risk.

Computed from expense ratio, AUM, sector concentration and SEBI mandate compliance. No paid review.

Performance

Returns for various periods, with category average and peer rank.

PeriodReturnsCategory avgRank
1W-0.95%-0.40%222/ 286
1M+2.06%+2.47%159/ 286
3M+6.67%+8.01%166/ 286
6M+13.52%+6.33%57/ 278
YTD+12.45%+6.03%64/ 273
1Y+9.62%+9.52%105/ 258
2Y+8.08%+5.82%68/ 203
3Y+20.46%+17.18%42/ 157
5Y+15.17%+14.76%53/ 125
7Y+23.23%+18.88%19/ 104
10Y+15.08%+14.74%38/ 81

Portfolio composition

Asset allocation

  • Equity99.30%
  • Cash0.70%

By market cap

  • Large cap35.17%
  • Mid cap23.60%
  • Small cap38.49%
  • Others2.74%

Concentration

Holdings

40

Avg market cap

₹49.9K Cr

Top 10 stocks

52.59%

Top 5 stocks

31.78%

Top 3 sectors

99.58%

Top holdings

Top 15 positions by weight, latest disclosure.

#InstrumentSectorWeight
  • 1

    Sun Pharmaceuticals Industries Ltd

    10.34%
  • 1

    Sun Pharmaceuticals Industries Ltd

    9.87%
  • 2

    Divi's Laboratories Ltd

    5.92%
  • 2

    Abbott India Ltd

    5.89%
  • 3

    Divi's Laboratories Ltd

    5.83%
  • 3

    HealthCare Global Enterprises Ltd

    5.45%
  • 4

    HealthCare Global Enterprises Ltd

    5.39%
  • 4

    Abbott India Ltd

    5.37%
  • 5

    Max Healthcare Institute Ltd Ordinary Shares

    5.17%
  • 5

    Max Healthcare Institute Ltd Ordinary Shares

    5.14%
  • 6

    Cipla Ltd

    5.10%
  • 6

    Cipla Ltd

    5.07%
  • 7

    Apollo Hospitals Enterprise Ltd

    4.25%
  • 7

    Rainbow Childrens Medicare Ltd

    4.23%
  • 8

    Rainbow Childrens Medicare Ltd

    4.23%

Fundamentals (vs category)

Portfolio-weighted ratios, compared with the category average.

MetricFundCategory avgDiff
  • P/E ratio40.4541.09-0.64
  • P/B ratio6.405.83+0.57
  • Price / Sales5.915.71+0.20
  • Price / Cash Flow30.4830.54-0.06
  • Dividend yield1.01%0.63%+0.38
  • Return on equity (ROE)18.68%16.57%+2.11

Risk metrics

Standard deviation, Sharpe, Sortino, Beta — all vs category average.

Metric1Y3Y5YCat 1YCat 3YCat 5Y
  • Standard deviation

    Volatility — lower means steadier returns.

    17.1916.7715.5014.9216.2915.44
  • Sharpe ratio

    Risk-adjusted return — higher is better.

    0.260.940.620.480.980.58
  • Sortino ratio

    Like Sharpe but only counts downside volatility.

    0.391.611.010.831.710.94
  • Beta

    1 = moves with the market. <1 = less volatile.

    0.931.000.950.940.950.94

Peers in Sectoral / Thematic

Other schemes in the same SEBI category, ranked by AUM.

Available plans & options

PlanOptionFull nameISIN

Click a plan to see its NAV and chart above. Direct plans have lower expense ratios than Regular — same portfolio, more of the return stays with you.